Literature DB >> 17982189

[Clinical application of vitamin K for hepatocellular carcinoma].

Toshihiko Mizuta1, Iwata Ozaki.   

Abstract

Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982189     DOI: CliCa071116931699

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  1 in total

1.  Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Authors:  Gang Wei; Meifang Wang; Terry Hyslop; Ziqiu Wang; Brian I Carr
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.